Significance of Plk1 regulation by miR‐100 in human nasopharyngeal cancer
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Polo‐like kinase 1 (Plk1) is a critical regulator of many stages of mitosis; increasing evidence indicates that Plk1 overexpression correlates with poor clinical outcome, yet its mechanism of regulation remains unknown. Hence, a detailed evaluation was undertaken of Plk1 expression in human nasopharyngeal cancer (NPC), the cellular effects of targeting Plk1 using siRNA in combination with ionizing radiation (RT) and potential upstream microRNAs (miRs) that might regulate Plk1 expression. Using immunohistochemistry, Plk1 was observed to be overexpressed in 28 of 40 (70%) primary NPC biopsies, which in turn was associated with a higher likelihood of recurrence (p = 0.018). SiPlk1 significantly inhibited Plk1 mRNA and protein expression, and decreased Cdc25c levels in NPC cell lines. This depletion resulted in cytotoxicity of C666‐1 cells, enhanced by the addition of RT, mediated by G2/M arrest, increased DNA double‐strand breaks, apoptosis, and caspase activation. Immunofluorescence demonstrated that the G2/M arrest was associated with aberrant spindle formation, leading to mitotic arrest. In vivo, transfection of C666‐1 cells and systemic delivery of siPlk1 decreased tumour growth. MicroRNA‐100 (miR‐100) was predicted to target Plk1 mRNA, which was indeed underexpressed in C666‐1 cells, inversely correlating with Plk1 expression. Using luciferase constructs containing the 3′‐UTR of Plk1 sequence, we document that miR‐100 can directly target Plk1. Hence, our data demonstrate for the first time that underexpressed miR‐100 leads to Plk1 overexpression, which in turn contributes to NPC progression. Targeting Plk1 will cause mitotic catastrophe, with significant cytotoxicity both in vitro and in vivo, underscoring the important therapeutic opportunity of Plk1 in NPC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860
Combinatorial microRNA target predictions
Krek, A., Grün, D., Poy, M. N., Wolf, R., Rosenberg, L., Epstein, E. J., MacMenamin, P., da Piedade, I., Gunsalus, K. C., Stoffel, M., et al. (2005) · Nature Genetics · doi:10.1038/ng1536 · Cited by 4,603 · cited 1×
“Thus far, 600 miRs have been described in the human genome; given that their target binding do not require 100% complementarity, a single miR could bind to as many as 200 target genes, rendering them as one of the largest classes of gene regulators in the mammalian system.(28) To date, the role of Plk1 in NPC remains…”
Background
Cited by
Cancer nanomedicine: from targeted delivery to combination therapy
Xu, X., Ho, W., Zhang, X., Bertrand, N., & Farokhzad, O. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.01.001 · Cited by 693
“PLK1 phosphorylates Cdc25C, regulates DNA damage checkpoints, microtubule nucleation, chromosomal condensation and segregation, and is an important target for therapeutic treatment [48].”
Bueno, M. J., & Malumbres, M. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.02.002 · Cited by 410
Lu, J., He, M.-L., Wang, L., Chen, Y., Liu, X., Dong, Q., Chen, Y.-C., Peng, Y., Yao, K.-T., Kung, H.-F., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-1850 · Cited by 381
The role of CDC25C in cell cycle regulation and clinical cancer therapy: a systematic review
Liu, K., Zheng, M., Lu, R., Du, J., Zhao, Q., Li, Z., Li, Y., & Zhang, S. (2020) · Cancer Cell International · doi:10.1186/s12935-020-01304-w · Cited by 287
MicroRNAs: new players in the DNA damage response
Hu, H., & Gatti, R. A. (2011) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjq042 · Cited by 180
“, 2009) and miR-100 targeting PLK1 (Shi et al., 2010).”
BackgroundInfluentialMicroRNA-99 Family Targets AKT/mTOR Signaling Pathway in Dermal Wound Healing
Jin, Y., Tymen, S. D., Chen, D., Fang, Z. J., Zhao, Y., Dragas, D., Dai, Y., Marucha, P. T., & Zhou, X. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064434 · Cited by 172
“In addition to the PI3K/AKT and mTOR signaling pathways, the miR-99 family has also been implicated in other pathways, including regulating cell cycle by targeting protooncogene PLK1 [34,45–47], an early trigger for G2/M transition.”
BackgroundMicroRNA profiling of adrenocortical tumors reveals miR-483 as a marker of malignancy
Patterson, E. E., Holloway, A. K., Weng, J., Fojo, T., & Kebebew, E. (2011) · Cancer · doi:10.1002/cncr.25724 · Cited by 171
“In fact, miR-100 was recently shown to regulate Polo-like kinase 1 (Plk1), a critical regulator of mitosis.(15)”
Background
Metadata
- Authors
- Shi, W., Alajez, N. M., Bastianutto, C., Hui, A. B. Y., Mocanu, J. D., Ito, E., Busson, P., Lo, K., Ng, R., Waldron, J., O'Sullivan, B., & Liu, F.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2009-12-30
- Volume
- 126
- Issue
- 9
- Pages
- 2036-2048
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W1997934236
- Cited by
- 149
- References
- 2
- FWCI
- 4.57
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.